在经历过去几年的冲高回落之后,2025年到底会怎么样,没人能够说得清楚,但在一片迷茫和焦虑之中,被业界称作“半个投资公司”的腾讯已经开始率先行动了。今年1月,腾讯在医药领域快速完成四笔投资,先后对癌症早筛企业Insighta、大分子研发商晟斯生物、细胞治疗药物开发商跃赛生物和肾脏疾病及相关慢性病制药公司礼邦医药进行了加码,其中对Insighta的一笔战略投资超过2亿元,而对礼邦医药的C轮投资额高达...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.